2 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow IT-101: new trials by email Literature Review of IT-101 trials Research Report on IT-101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRLX101 Plus Bevacizumab in Advanced RCC CRLX101 (Cerulean), Bevacizumab - Renal Cell Carcinoma | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 22 | 2012-06-01 | 2018-08-29 |
| Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer - Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 62 | 2006-05-01 | 2020-05-28 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Skin Neoplasms (1) · Thyroid Neoplasms (1)
Abramson Cancer Center at Penn Medicine (1) · NewLink Genetics Corporation (1)
United States (2)
Glenn Weiss, M.D. (1) · Jeffrey D. Neidhart, M.D. (1) · Naomi M Haas, MD (1) · Yun Yen, M.D., Ph.D. (1)